Compass Carter Osborne

HealthInvestor Awards 2024 WINNER
Executive Search Firm of the Year

Compass Carter Osborne

Life Sciences Newsletter

Q2 FY25

Matt Dixon
Principal
Life Sciences
07538 757 847
matt@compasscarterosborne.com
Connect

Introduction

Welcome to the second edition of our quarterly life sciences newsletter, the first we have published since our merger with Carter Schwartz and subsequent rebranding to Compass Carter Osborne. This move further strengthens our capabilities across life sciences and healthcare and is just the start of our rapid growth under the stewardship of our Board and new investors, Cow Corner.

Our life sciences division welcomed two new additions in Tarquin-Bennett Coles and Alex Boulger. Tarquin and Alex bring 25 and 17 years of experience respectively, with robust networks and track records in key markets across Europe and the US. We are delighted with the impact they have made already! We are proud to have recently won the prestigious Executive Search Firm of the Year accolade at the HealthInvestor awards ceremony. Our thanks go to all those who voted for us, our clients, and candidates who have partnered with us during the last 12 months.

Q2 saw the continuation of the pharma M&A activity that we saw in Q1, with the Vertex and Novartis acquisitions of Alpine Immune Sciences and Mariana Oncology, respectively, being especially noteworthy. A recently published report by PwC showed that deal volume across the sector has increased by 20% over the last year. However, the combined value of deals is down 2% from the previous 12-month period, mainly owing to the macroeconomic headwinds felt by the sector in 2022 and 2023 and their impact on valuations.

In our previous newsletter, I discussed the increasing M&A volumes and their impact on investor confidence, with money being put back into the hands of investors for future deployment. It has been great to see this come to fruition, with Sands Capital's $555m close of Pulse Fund III being just one example. Softening economic conditions, increasing drug approvals, and ongoing innovation are some of the main drivers of increased investor confidence. Antibody-drug conjugates, cell and gene therapies, and AI-enabled platforms dominate the areas of interest among our investor clients but look out for targeted protein degradation (TPD) as we enter the second half of the year.

To say we live in an interesting political climate would be an understatement: the recent change in government here in the UK; France's domestic turmoil and of course, all eyes are on the US for November's Presidential election. These events will inevitably impact our sector, and whether that impact is positive or negative remains to be seen. We have already seen the impact of the proposed BIOSECURE Act being felt, with 25% of US-based life sciences companies surveyed by L.E.K. Consulting seeking alternatives to their Chinese partners, and 2% have already begun the process. We have yet to see the long-term implications of the Inflation Reduction Act, and the election result will significantly impact its after-effect implementation.

We look ahead to the rest of the year with optimism and confidence in the sector and, ultimately, in jobs and hiring. The industry is not without its struggles, as recent layoffs announced by the likes of Pfizer, Gilead, and Takeda will attest to, but the overall trend is positive, and I expect this to continue.

Deals, Funding & IPOs

A selection of the most notable acquisitions, investments, partnerships and IPO news from Q2 of 2024

Vertex to acquire Alpine Immune Sciences

Vertex Pharmaceuticals announced its agreement to acquire Alpine Immune Sciences, Inc. This strategic move, valued at approximately $2.7 billion, aims to bolster Vertex's immunology pipeline. Alpine's expertise in immune system modulation will be leveraged to develop novel therapies for autoimmune and inflammatory diseases. The acquisition includes Alpine's proprietary platforms and promising pipeline, aligning with Vertex's commitment to advancing innovative treatments.

Merck to Acquire EyeBio

Merck (NYSE: MRK) has entered into an agreement to acquire EyeBiotech Limited (EyeBio), a biotechnology company focused on ophthalmology, for up to $3 billion. This acquisition, executed through a Merck subsidiary, includes an initial $1.3 billion cash payment and potential milestone payments totaling $1.7 billion contingent on developmental, regulatory, and commercial achievements. EyeBio's portfolio features Restoret™ (EYE103), a promising tetravalent, tri-specific antibody targeting the Wnt signaling pathway, currently in Phase 2 development for diabetic macular edema and neovascular age-related macular degeneration.

Merck aims to bolster its presence in ophthalmology through this acquisition, leveraging EyeBio's expertise and pipeline to advance innovative therapies for retinal diseases globally.

The transaction is anticipated to close in the third quarter of 2024, subject to regulatory

approvals and customary closing conditions, with EyeBio operating as a Merck subsidiary post-acquisition.

Novartis Acquires Mariana Oncology

Novartis has also made significant strides by acquiring Mariana Oncology, a company specializing in radiopharmaceuticals for cancer treatment, for up to $1.75 billion. This acquisition includes a $1 billion upfront payment and up to $750 million in potential milestone payments. Mariana's lead program, MC-339, targets small-cell lung cancer with an innovative radioligand therapy (RLT). This acquisition enhances Novartis' radiopharmaceutical capabilities and aligns with its strategy to expand in the oncology sector.

Boston Scientific Acquires Silk Road Medical

Boston Scientific is purchasing Silk Road Medical for $1.26 billion to enhance its portfolio in treating carotid artery disease. Silk Road's TCAR platform is a minimally invasive procedure for stroke prevention.

These strategic acquisitions demonstrate the ongoing consolidation and innovation in the biopharmaceutical and medical device industries, driven by the pursuit of advanced therapeutic solutions and market expansion.

References

Vertex Acquisition Announcement
Merck to Acquire EyeBio
Novartis Acquires Mariana Oncology
Boston Scientific Buys Silk Road Medical



Other Notable M&A Events

AbbVie acquires Celsius Therapeutics
Value: $250 mil
Date: June 27, 2024
Source

Great Point Partners acquires Lyocontract GmbH
Value: Undisclosed
Date: June 13, 2024
Source

Asahi Kasei acquires Calliditas Therapeutics
Value: $1.1 bn
Date: May 28, 2024
Source

Johnson & Johnson acquires Yellow Jersey Therapeutics
Value: $1.25 mil
Date: May 28, 2024
Source

MilliporeSigma acquires Mirus Bio
Value: $600 mil
Date: May 23, 2024
Source

Biogen acquires HI-Bio
Value: $1.15 bn
Date: May 22, 2024
Source

Genmab acquires ProfoundBio
Value: $1.8 bn
Date: May 21, 2024
Source

Johnson & Johnson acquires Proteologix
Value: $850 mil
Date: May 20, 2024
Source

Ono Pharmaceutical acquires Deciphera Pharmaceuticals
Value: $2.4 bn
Date: April 30, 2024
Source

Incyte acquires Escient Pharmaceuticals
Value: $750 mil
Date: April 23, 2024
Source

Century Therapeutics to acquire Clade Therapeutics
Value: $45 mil
Date: April 11, 2024
Source

Ascend acquires Beacon Therapeutics' CMC site in Alachua, Florida
Value: undisclosed
Date: April 09, 2024
Source

CNX Therapeutics acquires Loxapac and Parkinance LP
Value: €56.5 mil
Date: April 02, 2024
Source

Amber Therapeutics $100 mil Series A funding

10th June 2024

Amber Therapeutics secured $100 million in a Series A financing round. This funding will be instrumental in advancing their pioneering Amber-UI neuromodulation therapy aimed at treating mixed urinary incontinence (MUI). The therapy promises a breakthrough in providing a non-invasive, effective solution for MUI, significantly improving patient quality of life. The company is focused on moving towards US FDA approval, leveraging this substantial investment to accelerate clinical trials and regulatory processes. The round was led by prominent investors in the healthcare sector, demonstrating strong confidence in Amber Therapeutics' innovative approach and potential impact on the medical field.

Source

AltruBio $225 million Series B funding

21st May 2024

AltruBio has raised $225 million in a Series B funding round to advance its ulcerative colitis program. This funding comes after significant modifications to their checkpoint drug, showcasing the company's commitment to enhancing therapeutic efficacy. The new investment will primarily support mid-phase clinical trials to bring a new, effective treatment to patients suffering from ulcerative colitis. The funding round attracted a mix of existing and new investors, reflecting broad support for AltruBio's strategic direction and the potential of its therapeutic innovations.

Source

Syncona invests €30 million in iOnctura

20th June 2024

Roel Bulthuis, managing partner at SynconaSyncona, a London-based investment firm, has bolstered its portfolio by injecting over $100 million in series A and B funding into two promising cancer-focused biotechs. Leading an 80 million euros ($85.7 million) series B round for iOnctura, Syncona contributed 30 million euros ($32.1 million), securing a 23% stake in the Netherlands-based company. iOnctura is advancing roginolisib, an allosteric modulator of PI3K δ , which has shown promising efficacy and safety in a phase 1b trial for uveal melanoma. The funding will support further clinical trials of roginolisib in non-small cell lung cancer and primary myelofibrosis, aiming to capitalize on its unique precision in targeting the PI3K δ pathway, a significant achievement in cancer therapy, according to.

Additionally, Syncona has backed Yellowstone, a UK-based biotech spun out of the University of Oxford, with £16.5 million ($20.9 million) in series A financing. Founded on research by Dr.Paresh Vyas, Yellowstone focuses on developing soluble bispecific TCR-based therapeutics that target HLA class II presented peptides on cancer cells. Initially concentrating on acute myeloid leukemia (AML), Yellowstone plans to expand into ovarian, lung, colorectal, prostate, breast, renal cancers, and melanoma using its extensive biobank of patient samples.

Source

Other Notable Funding Rounds

Xaira Therapeutics new drug discovery
Value: $1 bn in funding
Date: April 24, 2024
Source

Sands Capital's Pulse Fund III
Value: $555M Close
Date: May 13, 2024
Source

LabGenius further developes its ML-driven antibody
Value: £35 mil Series B
Date: May 21, 2024
Source

Lycia Therapeutics completes series C
Value: $106.0 mil
Date: May 13, 2024
Source

Biofidelity accelerates commercialisation and pipeline
Value:$24 mil
Date: April 3rd, 2024
Source

TORL BioTherapeutics advances pipeline
Value: $158 mil
Date: April 10th, 2024
Source

Regeneron Pharmaceuticals builds new venture arm with commitment to invest in biotech and beyond
Value: $500 mil
Date: April 15th, 2024
Source

Cullinan Therapeutics Autoimmune market
Value: $280 mil
Date: April 17, 2024
Source

Sound Bioventures joins financing in UK oncolytic virus company Theolytics
Value: £19 mil ($24.5 mil)
Date: April 17th, 2024
Source

Augustine Therapeutics announces series A1 financing
Value: €17 mil
Date: June 26th , 2024
Source

Rapport Therapeutics IPO

6th June 2024

Rapport Therapeutics, Inc. has achieved a significant milestone by announcing the pricing of its initial public offering (IPO) of 8,000,000 shares of common stock at $17.00 per share. The company, a clinical-stage biotechnology firm specializing in developing precision medicines for central nervous system (CNS) disorders, is set to begin trading on the Nasdaq Global Market under the symbol "RAPP" starting June 7, 2024. In addition to the primary offering, Rapport has granted underwriters a 30-day option to purchase up to 1,200,000 additional shares at the IPO price.

Concurrently, Rapport will conduct a private placement of 1,058,824 shares at the public offering price per share to certain existing stockholders. Though not registered under the Securities Act of 1933, this private placement is expected to close on June 10, 2024, contingent upon customary closing conditions. Before deducting underwriting discounts, commissions, and other expenses, the combined gross proceeds from the IPO and private placement are anticipated to total approximately $154 million.

Founded on innovative research into receptor-associated proteins (RAPs) and their role in brain function, Rapport Therapeutics utilizes its proprietary RAP technology platform to develop targeted small molecule therapies. The company's lead clinical program, RAP-219, exemplifies this approach by selectively targeting RAPs expressed in specific brain regions. Currently, Rapport is advancing RAP-219 through clinical trials targeting focal epilepsy, peripheral neuropathic pain, and bipolar disorder. The company's pipeline includes additional preclinical and late-stage programs addressing various CNS disorders, including chronic pain and hearing disorders.

Source

Contineum Therapeutics IPO

6th June 2024

Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical-stage biopharmaceutical firm specializing in oral small molecule therapies targeting Neuroscience, Inflammation, and Immunology (NI&I) indications, has reported its financial results for the first quarter of 2024 alongside notable business advancements. Following a successful Initial Public Offering (IPO) in April 2024, which generated net proceeds of $108.0 million, the company has bolstered its financial position significantly, with a proforma cash balance reaching $225.9 million as of March 31, 2024. This funding is expected to sustain operations through 2027, supporting multiple clinical milestones for its lead candidates, PIPE-791 and PIPE-307.

In clinical developments, Contineum achieved a significant milestone with completing a Phase 1 trial for PIPE-791, a novel LPA1 receptor antagonist designed for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (MS). The trial demonstrated favorable safety, tolerability, and pharmacokinetic profiles across all tested cohorts, paving the way for a Phase 1b trial slated for the fourth quarter of 2024. This trial aims to further evaluate the drug's pharmacokinetics in relation to lung and brain receptor occupancy using PET imaging, which is crucial for dose selection in upcoming Phase 2 studies.

Further expanding its pipeline, Contineum nominated CTX-343 as its third internally developed candidate in January 2024. CTX-343, a peripherally restricted LPA1R antagonist, is currently undergoing preclinical studies with plans to file an Investigational New Drug Application (IND) in 2025. Additionally, the company presented promising data at the Myelin Gordon Conference highlighting high LPA1 receptor expression in brain tissue from MS patients, reinforcing the rationale for advancing PIPE-791 in progressive MS.

To bolster its strategic capabilities, Contineum made a significant move by appointing Olivia Ware, a seasoned pharmaceutical industry executive, to its Board of Directors in March 2024. With over two decades of experience in drug development and commercialization, Ware's insights are expected to play a crucial role in guiding Contineum's growth trajectory as it continues to advance its innovative therapies in the NI&I space.

Source

Alumis Plans IPO

27th June 2024

Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company based in South San Francisco, has successfully priced its initial public offering (IPO) of 13,125,000 shares of common stock at $16.00 per share. The offering, which commenced trading under the symbol "ALMS" on Nasdaq on June 28, 2024, is expected to close by July 1, 2024, pending customary closing conditions. Alumis has also granted the underwriters a 30-day option to purchase up to 1,968,750 shares of common stock at the IPO price.

In addition to the public offering, Alumis announced a concurrent private placement of 2,500,000 shares at $16.00 per share to AyurMaya Capital Management Fund, LP, an existing investor. These shares will not be registered under the Securities Act of 1933 and are subject to a 180-day lock-up agreement. The private placement is anticipated to close after the IPO, on or before July 22, 2024, contingent upon the IPO's completion.

The combined gross proceeds from the IPO and concurrent private placement are expected to total $250.0 million, excluding underwriting discounts, commissions, and other expenses. This capital infusion will support Alumis in advancing its pipeline of oral therapies, including ESK-001, an allosteric inhibitor of TYK2 under evaluation for moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005, a CNS-penetrant TYK2 inhibitor targeting neuroinflammatory and neurodegenerative diseases. Alumis utilizes a proprietary precision data analytics platform to develop therapies to optimize clinical outcomes for patients with immune-mediated diseases.

Source



Actuate Therapeutics to eye summer IPO

28th May 2024

Actuate Therapeutics is preparing to launch an initial public offering (IPO) to support its ongoing clinical trials of elraglusib, a drug targeting glycogen synthase kinase-3 beta (GSK-3 β). The Texas- and Ireland-based company aims to use IPO proceeds to advance a phase 2 trial for pancreatic cancer, as well as phase 1 studies in pediatric refractory cancer and a phase 2 portion for refractory Ewing sarcoma. Elraglusib, with its ability to disrupt cancer pathways involved in tumor cell invasion and chemoresistance, has shown early success in combination with Gemzar for pancreatic cancer treatment, offering a ray of hope in the fight against cancer.

This announcement follows Rapport Therapeutics' recent IPO ambitions, signaling a renewed interest in biotech offerings despite earlier market volatility in 2024. The move aligns with predictions from industry analysts, including MedicxiPartner Francesco De Rubertis, who foresee a reopening of the biotech IPO window throughout the summer. These developments suggest a growing confidence among biotech firms in accessing public markets to fund critical research and development efforts.

Source

Artiva Biotherapeutics refiles for $100 million IPO

28th June 2024

Artiva Biotherapeutics, a San Diego-based biotech firm founded in 2019, has filed with the SEC to raise $100 million in an initial public offering (IPO) on Nasdaq under the symbol ARTV. Specializing in off-the-shelf natural killer (NK) cell-based therapies for autoimmune diseases and cancers, Artiva focuses on allogeneic cell therapies derived from donor cells ready for immediate use without needing patient-specific customization. Through basket investigator-initiated studies, its lead candidate, AlloNK, is undergoing Phase 1/1b trials for lupus nephritis and multiple autoimmune indications. Artiva anticipates reporting initial trial data from at least one of these studies in the first half of 2025. The company previously attempted an IPO in 2021, which was withdrawn in late 2022 without setting specific terms. For the 12 months ending March 31, 2024, Artiva recorded $33 million in collaboration and license revenue. Jefferies, TD Cowen, and Cantor Fitzgerald are joint bookrunners for the IPO, although pricing details have not yet been disclosed.

Source

Clinical trial, research and drug approvals

A selection of the most notable clinical trials, R&D and drug approval news from Q2 of 2024

Alnylam Reports Positive Topline Results from Helios-B Phase 3 Study of Vutrisiran

24th June 2024

Alnylam Pharmaceuticals has announced positive topline results from the HELIOS-B Phase 3 study of Vutrisiran, a significant milestone in treating hereditary ATTR amyloidosis. The study demonstrated clinical success, showcasing Vutrisiran's positive outcomes in improving patient conditions. This therapeutic impact represents a potential advancement in the treatment of hereditary ATTR amyloidosis, offering hope for improved patient care. Moving forward, these results pave the way for regulatory approval and market entry, highlighting the future prospects of Vutrisiran in transforming the treatment landscape for this rare genetic disorder.

Source

Ultragenyx, Mereo drug reduces fractures in bone disorder study

12th June 2024

Ultragenyx and Mereo BioPharma reported that their drug setrusumab (UX143) led to a sustained reduction in fracture rates in osteogenesis imperfecta (OI) patients. In a Phase 2/3 study involving 24 patients, the median annualized fracture rate dropped to zero after nine months and maintained this reduction at 16 months. Additionally, lumbar spine bone mineral density (BMD) increased by 22% after 12 months. These results are promising as they advance to Phase 3 trials.

Source

Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2

21st June 2024

Arvinas announced new preclinical data for its PROTAC® investigational programs targeting BCL6 and LRRK2. The BCL6 degrader, ARV-393, showed anti-tumor activity in B-cell lymphoma models and is in phase 1 trials for non-Hodgkin lymphoma. The LRRK2 degrader program presented data indicating potential treatment for neurodegenerative diseases, demonstrating effective degradation and a favorable safety profile compared to kinase inhibitors. Both programs highlight the promise of PROTAC technology in addressing challenging diseases.

Source



Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS

20st June 2024

Sarepta Therapeutics has announced the expanded FDA approval of ELEVIDYS for treating Duchenne muscular dystrophy (DMD) in patients aged 4 and older. The FDA granted traditional approval for ambulatory patients and accelerated approval for non-ambulatory patients, pending further clinical trials. ELEVIDYS, a gene therapy, aims to address the genetic cause of DMD by delivering a transgene for micro-dystrophin production in skeletal muscle. This approval marks a significant milestone for gene therapy in treating DMD.

Source



Notable FDA approvals

ELEVIDYS (delandistrogene moxeparvovec-rokl)
Company: Sarepta Therapeutics
Date of Approval: June 20, 2024
Treatment for: Duchenne muscular dystrophy

PiaSky (Crovalimab-akkz)
Company: Genentech
Date of Approval: June 20, 2024
Treatment for: Paroxysmal Nocturnal Hemoglobinuria

Sofdra (Sofpironium) Topical Gel
Company: Botanix Pharmaceuticals
Date of Approval: June 18, 2024
Treatment for: Hyperhidrosis

Capvaxive (formerly V116)
Company: Merck
Date of Approval: June 17, 2024
Treatment for: Pneumococcal Disease Prophylaxis

Vigafyde™ (Vigabatrin) Oral Solution
Company: Pyros Pharmaceuticals
Date of Approval: June 17, 2024
Treatment for: Infantile Spasms

Yimmugo (immune globulin intravenous, human-dira) Liquid
Company: Grifols USA
Date of Approval: June 13, 2024
Treatment for: Primary Immunodeficiency Syndrome

Iqirvo (Elafibranor) Tablets
Company: Ipsen Biopharmaceuticals
Date of Approval: June 10, 2024
Treatment for: Primary Biliary Cholangitis

Rytelo (Imetelstat for Injection)
Company: Geron Corporation
Date of Approval: June 6, 2024
Treatment for: Myelodysplastic Syndrome

mResvia (Respiratory Syncytial Virus Vaccine) Injection
Company: Moderna
Date of Approval: May 31, 2024
Treatment for: RSV

Bkemv (Eculizumab-aeeb for Injection)
Company: Amgen
Date of Approval: May 28, 2024
Treatment for: Paroxysmal Nocturnal Hemoglobinuria, Hemolytic Uremic Syndrome

Onyda XR (Clonidine Hydrochloride)
Company: Tris Pharma
Date of Approval: May 24, 2024
Treatment for: ADHD

Yesafili (Aflibercept-jbvf) Injection
Company: Biocon Biologics
Date of Approval: May 20, 2024
Treatment for: Macular Degeneration, Macular Edema Following Retinal

Opuviz (Aflibercept-yszy) Injection
Company: Samsung Bioepis
Opuviz (Aflibercept-yszy) Injection
Company: Samsung Bioepis
Date of Approval: May 20, 2024
Treatment for: Macular Degeneration, Macular Edema Following Retinal Vein Occlusion , Diabetic Macular Edema, Diabetic Retinopathy

Imdelltra (Tarlatamab-dlle) for Injection
Company: Amgen
Date of Approval: May 16, 2024
Treatment for: Small Cell Lung Cancer

Myhibbin (Mycophenolate Mofetil) Oral Suspension
Company: Azurity Pharmaceuticals
Date of Approval: May 1, 2024
Treatment for: Organ Transplant, Rejection Prophylaxis

Beqvez (Fidanacogene Elaparvovec-dzkt) Injection
Company: Pfizer
Date of Approval: April 26, 2024
Treatment for: Hemophilia B
Xolremdi (Mavorixafor) Capsules
Company: X4 Pharmaceuticals
Date of Approval: April 26, 2024
Treatment for: WHIM Syndrome

Libervant (Diazepam) Buccal Film
Company: Aquestive Therapeutics
Date of Approval: April 26, 2024
Treatment for: Seizure Clusters

Hercessi (Trastuzumab-strf) for Injection
Company: Accord BioPharma
Date of Approval: April 25, 2024
Treatment for: Breast Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma

Pivya (Pivmecillinam) Tablets
Company: Utility Therapeutics
Date of Approval: April 24, 2024
Treatment for: Urinary Tract Infection

Ojemda (Tovorafenib) Tablets and Oral Suspension
Company: Day One Biopharmaceuticals
Date of Approval: April 23, 2024
Treatment for: Low-Grade Glioma

Executive Moves

A selection of people moves & insights from Q2 2024

Cytiva Appoints Pierre-Alain Ruffieux as Chief Operating Officer

Source

Tectonic Therapeutic Appoints Daniel Lochner as Chief Financial Officer

Source

Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer

Source

Cosmo Pharmaceuticals Appoints Giovanni Di Napoli as Chief Executive Officer

Source

Ocular Therapeutix Hooks Chief Medical Officer from Beacon

Source

Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer

Source

Arvinas Appoints Ian Taylor as President of Research and Development

Source

Arvinas Appoints Angela Cacace as Chief Scientific Officer

Source

Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer Officer

Source

Novartis Appoints Giovanni Caforio as Board Chairman

Source

Inovio Appoints Steven Egge as Chief Commercial Officer

Source

Lupin Manufacturing Solutions Appoints Abdelaziz Toumi as Chief Executive Officer

Source

Amarin re-Appoints Aaron Berg as Chief Executive Officer

Source

Geoff Dobson
Non-Executive Advisor

0208 036 3530
geoff@compasscarterosborne.com
Connect with Geoff on LinkedIn

Biography

Geoff Dobson is a Non-Executive Advisor to Compass who brings more than 30 years' life sciences experience including over a decade in executive search and leadership assessment. A former Director at Coulter Partners, he is Managing Partner of Newgrange Consultants – a leadership assessment and development business. An expert in occupational psychology, Geoff's PhD research focused on leadership effectiveness. He is also a Charted Fellow of the CIPD.

Tarquin Bennett-Coles
Director

07876 564 645
tarquin@compasscarterosborne.com
Connect with Tarquin on LinkedIn

Biography

Tarquin is a Director in Compass Carter Osborne's Life Sciences practice, focussing on senior leadership roles across biotech, pharma, medtech, and diagnostics companies to life science service businesses and healthcare consultancies.

Tarquin has handled a vast number of complex senior assignments across the C-suite, and executive leadership life sciences landscape. His career has also included successfully supporting AstraZeneca as Global Talent Scout for its Innovative Medicines and Early Development (IMED) Biotech Unit and biologics business units.

Holding a BEd (Hons) degree from Homerton College, University of Cambridge, Tarquin is also an advisor to Little Bean Journey; a volunteer and advocate for Beacon for Life Sciences, a rare disease charity, Cambridge Rape Crisis Centre and the school age STEM charity Form the Future.

Alex Boulger
Principal

07943 864 457
alex@compasscarterosborne.com
Connect with Alex on LinkedIn

Biography

Alex joined Compass Carter Osborne in 2024 as a Principal, bringing over a decade of search experience within the life science sector, having recently moved from a dedicated life sciences search firm. He will be focused on C-suite, board and executive leadership appointments for high growth, listed and investor-backed companies in the Pharma, Biotech and MedTech space across EMEA and North America. Alex's career in executive search for the global scientific markets spans several decades, and has been responsible for delivering numerous searches supporting and advising clients to build world-class leadership teams during this time.

Matt Dixon
Principal

07538 757 847
matt@compasscarterosborne.com
Connect with Matt on LinkedIn

Biography

Matt joined Compass Carter Osborne in 2023 to enhance our presence in the Life Sciences sector. He has over six years of experience partnering with listed and PE backed Pharma, Biotech, MedTech and Pharma Services firms across EMEA and North America with a focus on C-suite and executive leaership mandates. Example placements include, but are not limited to, Managing Director, General Manager and other P&L ownership positions. He has also completed VP searches in Strategy, Commercial, Clinical, Medical, Regulatory and Technical Operations functions.

Kieran Mouser
Head of Research

07860 355 504
kieran@compasscarterosborne.com
Connect with Kieran on LinkedIn

Biography

Kieran is an Associate Director and Head of Research at Compass Carter Osborne. Kieran has worked for our executive search arm for many years and manages our dedicated in-house research team. In addition, he personally delivers high level mandates across the health, social care, education and life sciences sectors. Those C-suite mandates typically cover Finance, M&A, Commercial, Change, Operations, HR and Non-Exec Board positions. These mandates are based in the UK, across Europe and internationally.

Ray Rodriguez
Research Associate

07787 272 612
ray@compasscarterosborne.com
Connect with Ray on LinkedIn

Biography

Ray joined Compass Carter Osborne in 2023 as Research Associate. Prior to joining, he was Research Executive for an international technology executive search organisation; predominantly for fast-growth enterprise software and SaaS companies globally, specialising in attracting and hiring senior leadership talent. Ray holds an MSc in Accounting and Data Analytics, where he focused on applications of artificial intelligence in stock market decision making, and a BA in Hospitality Management with Tourism from the University of Portsmouth.